Clinical Trial Update: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update reports results for durvalumab (MEDI4736) in combination with AZD9150 or AZD5069 in patients with advanced solid tumors and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)
• AZD9150
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-11-23